Why the study?
Does left cardiac sympathetic denervation prevent syncope or cardiac arrest in symptomatic patients with long QT syndrome refractory to beta blockade?
Does left cardiac sympathetic denervation prevent syncope or cardiac arrest in symptomatic patients with long QT syndrome refractory to beta blockade?
Left cardiac sympathetic denervation is an effective treatment option for long QT syndrome patients who remain symptomatic despite beta-blocker therapy.
May support left cardiac sympathetic denervation in refractory long QT syndrome; leaves open confirmation in randomized trials.
The idiopathic long QT syndrome (LQTS) is an unusual clinical disorder characterized by a prolongation of the QT interval and by syncopal episodes occurring among young subjects, most often during exercise, stress, or other conditions of increased sympathetic activity. Both an imbalance in sympathetic innervation and an intracardiac defect in membrane currents have been proposed as pathogenetic mechanisms. The latter appears substantiated by recent advances in molecular genetics showing a linkage on chromosomes 11, 3, 7, and 4, with identification of the genes for chromosomes 3 and 7. For symptomatic patients with the long QT syndrome, beta-adrenergic blockade, with efficacy in approximately 80% of patients, currently remains the therapy of first choice. For the patients who continue to suffer syncope or cardiac arrest despite beta blockade, evidence has been provided that left cardiac sympathetic denervation represents a very effective treatment. The improvement in the understanding of the molecular mechanisms involved may soon lead to gene specific therapy in most long QT patients.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: